...
首页> 外文期刊>Bone marrow transplantation >Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
【24h】

Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.

机译:如果耐药性继发性继发性急性早幼粒细胞白血病复发,自体移植前应采用砷和全反式维甲酸作为诱导疗法。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Arsenic trioxide has recently been reported to be successful in the treatment of promyelocytic leukemia. Several concerns about the use of this toxic agent are currently reducing its potential clinical use even in severely ill patients. In this report we describe the results achieved by As2O3 with all-trans retinoic acid in a patient suffering from secondary, relapsed, resistant promyelocytic leukemia. Several complications, including sepsis and an extensive area of skin necrosis, did not allow us to treat the patient further with chemotherapy. With As2O3 and ATRA therapy, the patient obtained a complete molecular remission without any significant toxicity and, subsequently, it was possible to perform a bone marrow autograft in a state of complete remission.
机译:最近有报道称三氧化二砷可成功治疗早幼粒细胞白血病。目前,即使在重病患者中,使用这种有毒药物的一些担忧也正在降低其潜在的临床用途。在本报告中,我们描述了As2O3与全反式维甲酸在患有继发性,复发性,耐药性早幼粒细胞白血病的患者中获得的结果。包括脓毒症和大面积皮肤坏死在内的数种并发症使我们无法通过化学疗法进一步治疗患者。通过As2O3和ATRA治疗,患者获得了完全的分子缓解,而没有任何明显的毒性,因此,可以在完全缓解的状态下进行骨髓自体移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号